C4A and lobular neoplasia: In a recent study of severe LN patients, that included patients on combination therapy of rituximab and belimumab, the C4d/C4 ratio correlated better with levels of anti-dsDNA and anti-C1q antibodies than stand-alone measurement of C4d or C4 (28).